-+ 0.00%
-+ 0.00%
-+ 0.00%

Idorsia's daridorexant meets primary endpoint in Phase 2 pediatric insomnia trial

PUBT·10/23/2026 15:46:06
Listen to the news
Idorsia's daridorexant meets primary endpoint in Phase 2 pediatric insomnia trial
  • Idorsia announced positive Phase 2 results for daridorexant in pediatric insomnia, presented at Sleep Europe 2026.
  • The trial met its primary endpoint, showing improved sleep duration, including in participants with neurodevelopmental disorders.
  • Treatment was well tolerated across studied doses, with no new safety findings or withdrawal symptoms observed.
  • A pediatric Phase 3 program is expected to begin in the second half of 2027.
  • Daridorexant is marketed as QUVIVIQ for adult insomnia; pediatric use remains investigational and is not approved in any country.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231145OMX_____CNEWS_EN_GNW1001279533_en) on October 23, 2026, and is solely responsible for the information contained therein.